Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6178258 | 0.80 | MALT1 (0.51) | CA12CA9TDP1 | |
| SCHEMBL7711293 | 0.78 | SLC2A1 (0.49) | L3MBTL1HSD17B10ALDH1A1TSHRKDM4E | |
| SCHEMBL11316710 | 0.76 | HSD17B10 (0.45) | L3MBTL1MAPK1CYP1A2HSD17B10ALOX15 | |
| SCHEMBL9297733 | 0.76 | MTNR1A (0.45) | MTNR1AMTNR1BL3MBTL1CYP1A2HSD17B10 | |
| SCHEMBL6860751 | 0.75 | SLC2A1 (0.47) | MAPK1HSD17B10ALDH1A1KDM4ETDP1 | |
| SCHEMBL852975 | 0.73 | POLB (0.40) | HSD17B10CLK4ALDH1A1TSHRKDM4E | |
| SCHEMBL14182015 | 0.73 | NPSR1 (0.38) | L3MBTL1MAPK1CYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL6963178 | 0.73 | KMT2A (0.34) | L3MBTL1CYP1A2ALDH1A1KDM4ETDP1 | |
| SCHEMBL6951347 | 0.73 | CA12 (0.38) | CA12CA4CA7CA9CA14 | |
| SCHEMBL6947512 | 0.73 | TDP1 (0.36) | ALDH1A1KDM4ETDP1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946180-A4 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORP (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20020032187-A1 | Method for stimulating bone formation | SMITHKLINE BEECHAM CORPORATION | 2002-03-14 | — | — | US | disclosed |
| US-6159964-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0946180-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0906103-A4 | — | — | 1999-04-07 | — | — | EP | disclosed |
| EP-0906103-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-07 | — | — | EP | disclosed |
| WO-1998015278-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-16 | — | — | WO | disclosed |
| WO-1997024124-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032187-A1 | Method for stimulating bone formation | BMP2, BMP4, SOST | CA12 1939/4885CA4 1870/4885CA7 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.